Description

Frag 176–191 – 5 mg

(Human Growth Hormone Fragment 176–191)

Frag 176–191 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176 through 191. This region has been shown in preclinical studies to independently regulate fat metabolism without influencing blood-glucose levels or promoting cell proliferation associated with full-length hGH.

Research has focused on Frag 176–191 for its potential lipolytic (fat-burning) and anti-lipogenic (fat-storage-inhibiting) properties, making it a valuable tool in experimental models investigating metabolism, adipose regulation, and energy homeostasis.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• Lipolysis stimulation: Activates beta-adrenergic and lipolytic pathways, promoting the breakdown of stored triglycerides.

• Inhibition of lipogenesis: Reduces the conversion of excess nutrients into body fat.

• No GH receptor activation: Does not increase IGF-1 levels or induce mitogenic activity, differentiating it from native hGH.

• Metabolic regulation: Enhances fat oxidation and supports cellular energy balance.

• Selective mechanism: Mimics the beneficial metabolic actions of growth hormone without broader endocrine effects.

---

Potential Benefits (Based on Preclinical Research):

• Enhanced fat oxidation and metabolic rate

• Reduction of adipose tissue accumulation

• Preservation of lean muscle mass

• Improved energy utilization in metabolic research models

• Investigated for applications in obesity, lipid metabolism, and mitochondrial-function studies

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.